Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Novo Nordisk stock slumped early Monday as the drugmaker was facing a potential hit to revenue from several different ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Tesla Shares in electric vehicle maker Tesla have climbed back to their highest point since February, amid investor optimism ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...